Bayer's Levitra improves erections 81%

German drugmaker Bayer AG says that, in the first study of its kind in men with erectile dysfunction who had not been previously treated with a phosphodiesterase type 5 inhibitor, 81% of men who took its drug Levitra (vardenafil) reported improved erections versus 30% for those on placebo (p<0.0001).

According to the data from the 12-week, 260-patient multicenter, randomized, double-blind, placebo-controlled study, which were presented at the annual meeting of the European Association of Urology conference, held in Paris, France, 78% of men were able to maintain their erections to complete intercourse vs 41% with placebo (p<0.0001).

Couples in the study also reported that Levitra significantly improved male confidence (64% vs 41% for men; and 60% vs 37% for partners), pleasure (67% vs 44% for men; and 64% vs 38% for partners) and satisfaction with erection (60% vs 28% for men; 58% vs 27% for partners), orgasm (60% vs 32% for men; 56% vs 32% for partners).